Skip to main content
79°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Eisai Co Ltd
Recent news which mentions Eisai Co Ltd
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
January 15, 2025
Tags
Health care industry
Bristol/Myers Squibb Co
Biotechnology
From
CNBC.com News
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
October 30, 2024
Tags
Biogen Inc
Pharmaceuticals
Health care industry
From
CNBC.com News
5 things to know before the stock market opens Monday
September 09, 2024
Tags
Economy
Eisai Co Ltd
Investment strategy
From
CNBC.com News
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
September 08, 2024
Tags
Eisai Co Ltd
Breaking News: Business
Business News
From
CNBC.com News
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
July 30, 2024
Tags
Companies
Breaking news
US: News
From
CNBC.com News
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
July 30, 2024
Tags
Business
US: News
Companies
From
CNBC.com News
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
July 26, 2024
Tags
US: News
Business
Companies
From
CNBC.com News
Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug
June 11, 2024
Tags
Investment Strategy
Business
U/S/ Markets
From
CNBC.com News
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
April 24, 2024
Tags
US: News
Business
Breaking news
From
CNBC.com News
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
March 08, 2024
Tags
Companies
Business
US: News
From
CNBC.com News
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
February 20, 2024
Tags
Eisai Co Ltd
Healthy Returns
Biotech and Pharmaceuticals
From
CNBC.com News
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
February 13, 2024
Tags
Health & Science
Biotech and Pharmaceuticals
Earnings
From
CNBC.com News
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
January 31, 2024
Tags
Companies
US: News
Business
From
CNBC.com News
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
December 20, 2023
Tags
Companies
Amgen Inc
Business
From
CNBC.com News
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
December 02, 2023
Tags
Eli Lilly and Co
Science
Health & Science
From
CNBC.com News
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
October 25, 2023
Tags
Business News
Eisai Co Ltd
Biotechnology
From
CNBC.com News
5 things to know before the stock market opens Tuesday
July 18, 2023
Tags
Eli Lilly and Co
JPMorgan Chase & Co
Business
From
CNBC.com News
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
July 17, 2023
Tags
Eli Lilly and Co
Science
Health & Science
From
CNBC.com News
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
July 08, 2023
Tags
Biotech and Pharmaceuticals
Science
Health & Science
From
CNBC.com News
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
July 07, 2023
Tags
Business News
Eisai Co Ltd
Law and Regulation
From
CNBC.com News
Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more
July 07, 2023
Tags
stocks
Rivian Automotive Inc
Markets
From
CNBC.com News
Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug
July 07, 2023
Tags
Asia Markets
Science
Pharmaceuticals
From
CNBC.com News
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
July 06, 2023
Tags
US: News
Business
Social issues
From
CNBC.com News
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval
June 09, 2023
Tags
US Top News and Analysis
US: News
Social issues
From
CNBC.com News
Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action
June 07, 2023
Tags
US: News
Social issues
Business
From
CNBC.com News
Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
May 12, 2023
Tags
Eisai Co Ltd
Breaking News: Business
Politics
From
CNBC.com News
Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments
May 01, 2023
Tags
Biogen Inc
Health care industry
Disease outbreaks
From
CNBC.com News
Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
April 30, 2023
Tags
Disease outbreaks
Health care industry
World News
From
CNBC.com News
Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says
April 26, 2023
Tags
US: News
Social issues
Business
From
CNBC.com News
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
April 25, 2023
Tags
Biotechnology
Health care industry
Biogen Inc
From
CNBC.com News
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.